Genentech, a member of the Roche Group, announced that new data from its CD20xCD3 T-cell engaging bispecific antibody program, including eight oral presentations, were presented at the 65th American Society of Hematology Annual Meeting & Exposition, December 9-12, 2023.
¿Cuán pesado puede ser un elemento químico? Unos científicos han descubierto que algunas estrellas fueron capaces de producir elementos químicos con números másicos mucho mayores de 260, o sea más pesados que cualquier elemento de la tabla peri …
Se crean en el cosmos elementos químicos más allá de la tabla periódica Read More »
MorphoSys AG announced comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis.
InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that the latest data from InnoCare’s oncology studies were presented at the 65th American Society of Hematology Annual Meeting.
Latest Data of InnoCare’s Oncology Pipelines Presented at the 65th Annual Meeting of ASH Read More »
Positive results from the 24-week and long-term extension period of the pivotal ALPHA Phase III trial showed danicopan as add-on to standard of care C5 inhibitor therapy ULTOMIRIS® or SOLIRIS® continued to demonstrate clinical benefit for patients with paroxysmal nocturnal hemoglobinuria who experience clinically significant extravascular hemolysis.
AbbVie and Genmab A/S announced that adult patients with relapsed/refractory follicular lymphoma previously treated with two or more prior therapies experienced strong and durable responses with high overall response and complete response rates when treated with epcoritamab, an investigational, subcutaneously administered T-cell engaging bispecific antibody.
bluebird bio, Inc. announced new and updated efficacy, safety and health-related quality of life data from the Phase 1/2 HGB-206 Group C and Phase 3 HGB-210 studies of lovotibeglogene autotemcel gene therapy for sickle cell disease through five years of follow-up.
Blueprint Medicines Corporation announced data showcasing its commitment to advance the scientific understanding and treatment of systemic mastocytosis at the 65th American Society of Hematology Annual Meeting and Exposition being held December 9-12 in San Diego.
Genentech, a member of the Roche Group, announced that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® in previously untreated or minimally treated infants with severe hemophilia A without factor VIII inhibitors.
Mirum Pharmaceuticals, Inc. announced that on December 8, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 25,750 shares of common stock and 12,880 restricted stock units to five new employees under Mirum’s 2020 Inducement Plan.
